Arthneeti
MP

Mankind Pharma Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Mankind Pharma Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹2,384
Market cap₹1.0L Cr
P/E47.0
Updated23 Aug 2026
Read5 min read

The short version

BSV (Biosimilars) is expected to grow at around 18%-20% overall in the coming year, with sequential quarterly improvement (Q2 > Q1, Q3 > Q2). Profit After Tax (PAT) declined 17.4% YoY in Q1 FY26 due to higher finance and depreciation costs linked to BSV consolidation.

From Mankind Pharma Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • BSV (Biosimilars) is expected to grow at around 18%-20% overall in the coming year, with sequential quarterly improvement (Q2 > Q1, Q3 > Q2).
  • International business growth for BSV is expected to be upwards of 20%, supported by market penetrations like Russia and newer markets.
  • Domestic BSV growth is driven by both Rx and specialty segments (e.g., fertility drugs with 10-35%+ growth, anti-snake venom with high double-digit growth).
  • Mankind's domestic business organic growth is at 10% year-on-year, with overall company growth (including BSV) at 24.5%.
  • Modern trade and e-commerce channels in the OTC segment grew ~50% YoY, with channel share increasing to 11%.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Mankind Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Mankind Pharma is investing in a new biologic/biosimilar facility at Baroda, aimed at scaling up and de-risking operations from their Ambernath site (BSV facility).
  • The Capex for Phase 1 of this biologic facility is estimated around Rs. 150 to Rs. 200 crore, expected to be completed by the end of the next calendar year.
  • Approximately Rs. 100 crore of this Capex is anticipated as cash outflow in FY26.
  • This Capex includes all biologic products of BSV, including Anti-D and Anti-ID.
  • The biologic facility development is planned in two phases: first for drug substance and second for drug products.
  • Mankind is also expanding its biological R&D facilities to strengthen innovation capabilities.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Mankind Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided from the Mankind Pharma Q1 FY26 earnings call does not explicitly mention the current or expected order book or pending orders. However, relevant operational and growth updates include: - BSV business expected to grow 18%-20% with increasing traction internationally and in specialty segments. - Ongoing international product registrations and approvals, including recent board approval for Russia. - New biological facility at Ambernath under construction to scale up and de-risk BSV operations, with Capex around Rs. 150-200 crores expected by end of calendar year 2026. - Expansion in R&D and manufacturing capacities to support pipeline and export markets, including Dydrogesterone facility running at ~60% capacity, expected to increase as approvals arrive.

2 more points management made on order book & pipeline

Mankind Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹3.4K Cr, net profit ₹559 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Mankind Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences Ltd (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals Ltd (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories Ltd (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem Ltd (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Mankind Pharma Ltd Q1 FY26 results?

BSV (Biosimilars) is expected to grow at around 18%-20% overall in the coming year, with sequential quarterly improvement (Q2 > Q1, Q3 > Q2). Profit After Tax (PAT) declined 17.4% YoY in Q1 FY26 due to higher finance and depreciation costs linked to BSV consolidation.

What is Mankind Pharma Ltd share price analysis?

Mankind Pharma Ltd currently shows a neutral. The stock trades at a P/E of 47.0 with a market cap of ₹100,160 Cr. Investors should review the full earnings analysis for detailed insights.

Is Mankind Pharma Ltd planning capital expenditure?

Mankind Pharma is investing in a new biologic/biosimilar facility at Baroda, aimed at scaling up and de-risking operations from their Ambernath site (BSV facility). - The Capex for Phase 1 of this biologic facility is estimated around Rs.

Keep Mankind Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.